Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (8270)	1/13/1999 3:47:00 AM
From: Tharos	Read Replies (1) \| Respond to of 17367

Yes, I hope we hear something soon. I figured they may be delaying info because of the move and the desire to make the tax burden as small as possible. But now the move is over. I lean towards DSMB recommendation for approval, but with just barely enough statistical significance to pass. Reason being other improved treatments. Yet I feel the quality of treatment in regards to amputations and deformations will give Neuprex the edge it needs to get the go-ahead.